Key clinical point: Opicapone, a once-daily COMT inhibitor approved in the European Union and under development in the United States, was associated with increases in the amount of on-time without dyskinesia in patients with Parkinson’s disease and motor fluctuations.
Major finding: Increases of up to 2.0 hours in on-time without dyskinesia were reported.
Study details: Pooled analyses of the international phase 3 BIPARK-1 and BIPARK-2 trials and their respective open-label extension studies.
Disclosures: Dr. LeWitt provided disclosures related to Neurocrine Biosciences, as well as Acadia, Acorda, Adamas, BioElectron Technology, Biotie, Britannia, Intec, Jazz Pharmaceuticals, Lundbeck, the Michael J. Fox Foundation for Parkinson’s Research, Merz, NeuroDerm, the Parkinson Study Group, Pfizer, Prexton, Sage, Scion, Sunovion, SynAgile, and US WorldMeds.
LeWitt P et al. AAN 2019, Abstract S4.003.